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The neuropilins NRP1 and NRP2 are multifunctional glycoproteins that have been
implicated in several cancer-related processes including cell survival, migration,
and invasion in various tumor types. Here, we examine the role of neuropilins in
hepatoblastoma (HB), the most common pediatric liver malignancy. Using a combination
of immunohistochemistry, RNA analysis and western blotting, we observed high level
expression of NRP1 and NRP2 in 19 of 20 HB specimens and in a majority of human HB
cell lines (HUH6 and five cell lines established from patient-derived xenografts) studied
but not in normal hepatocytes. Silencing of NRP2 expression in HUH6 and HB-282
HB cells resulted in decreased cell viability, impaired cytoskeleton remodeling, and
reduced cell motility, suggesting that NRP2 contributes to the malignant phenotype. We
propose that neuropilins warrant further investigation as biomarkers of HB and potential
therapeutic targets.
Keywords: neuropilin, hepatoblastoma, pediatric cancer, cell viability, migration, liver
INTRODUCTION
Hepatoblastoma (HB) is the most common primary liver malignancy in the pediatric population
with an incidence of 1.9 cases per million (1, 2). Preterm birth, low birthweight, and certain
genetic conditions such as Beckwith-Wiedemann syndrome and Familial Adenomatous Polyposis
are associated with increased risk of HB. In most HB cases, however, the etiology of the disease
remains unidentified (3, 4). HB histology resembles embryonal or fetal liver, and low differentiation
stage associates with poor prognosis (5). The molecular pathways involved in the pathogenesis of
HB are not fully understood, although aberrant activation of WNT/β-catenin signaling is present
in the majority of these tumors (6, 7).
The neuropilin (NRP) family contains two single-passing transmembrane glycoproteins,
neuropilin-1 (NRP1) and neuropilin-2 (NRP2), sharing 44% amino acid sequence homology (8).
NRPs interact with plethora of cancer associated pathways encompassing signaling mediated by
vascular endothelial growth factors, semaphorins, transforming growth factor beta, hepatocyte
growth factor, platelet derived growth factors, and integrins (9–16). NRPs were originally
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documented as regulators for neurogenesis, angiogenesis and
lymphangiogenesis, but there is growing evidence that these
glycoproteins are involved in the initiation and progression
of various malignancies including hepatocellular carcinoma,
pancreatic adenocarcinoma, colorectal adenocarcinoma, breast
cancer, and non-small cell lung cancer (17–23). More precisely,
overexpression of NRPs has been linked to increased cancer
cell viability, motility and invasiveness, as well as resistance to
chemotherapy (24–27).
In normal liver, neither NRP1 nor NRP2 is expressed in
hepatocytes, whereas NRP1 immunoreactivity is evident in
hepatic stellate cells (HSCs) and liver sinusoidal endothelial cells
(LSECs) (28, 29).
Here, we characterize the expression patterns of NRP1 and
NRP2 in human HB specimens and cell lines. Additionally, we




Archival formalin-fixed paraffin-embedded (FFPE) HB
patient samples (n = 20) and normal liver control (NL,
n = 4) samples were obtained from the Helsinki Biobank
at Helsinki University Hospital. The HB samples were
originally collected at the time of surgical treatment,
whereas the NL samples were from liver transplantation
donors. This study was approved by Helsinki University
Hospital institutional ethical committee (HUS/3319/2018)
and conducted in accordance with Finnish bylaws. Informed
consent was obtained when samples were deposited to the
Helsinki Biobank.
Immunohistochemistry
FFPE samples were cut to 5-µm sections and deparaffinized
with xylene. For antigen epitope unmasking, samples were
treated with antigen target retrieval solution (pH 9; Dako,
Glostrup, Denmark) for 30min at +98◦C. Next, endogenous
peroxidase activity was blocked with 3% hydrogen peroxidase
and non-specific binding was averted with 0.4% casein (both
solutions from Novolink Polymer Detection System Kit; Leica,
Newcastle, UK). Primary antibody incubations were performed
either at +4◦C for overnight (NRP2 at dilution 1:2,000;
sc-13117, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
or at room temperature for 1 h (NRP1 at dilution 1:3,000;
ab81321, Abcam, Cambridge, MA). Antibody binding was
visualized with polymerized reporter enzyme staining system
(Novolink Polymer Detection System Kit). Positive LSEC
staining was used as an internal control for both antibodies.
Immunoreactivity was scored based on intensity (negative,
low/intermediate, or high) by two separate observers. Imaging
Abbreviations: CXCR4, C-X-C chemokine receptor type 4; FFPE, formalin-fixed
paraffin-embedded; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HB,
hepatoblastoma; HSC, hepatic stellate cell; LSEC, liver sinusoidal endothelial cell;
NRP1, neuropilin-1; NRP2, neuropilin-2; NT, non-targeting; PDX, patient-derived
xenograft; PPIG, peptidyl-prolyl cis-trans isomerase G; siRNA, small interfering
RNA.
was performed using 3DHISTECH Panoramic 250 FLASH II
digital slide scanner at Genome Biology Unit (Research Programs
Unit, Faculty of Medicine, University of Helsinki Biocenter,
Helsinki, Finland).
Cell Lines and Primary Hepatocyte Culture
Human HB cell line HUH6 was obtained from Japanese
Collection of Research Bioresources Cell Bank (Osaka, Japan).
HB cell lines established from patient-derived xenografts (PDX;
HB-282, HB-295, HB-279, HB-284, and HB-243) were provided
by XenTech (Evry, France) (30). Primary hepatocytes from
a 4-year-old Caucasian male donor with non-liver related
cause of death were purchased from Lonza (Basel, Switzerland)
and cultured as instructed. HUH6 cells were maintained
with Dulbecco’s modified Eagle’s medium (DMEM)-glutaMAX
supplemented with 10 % fetal bovine serum (FBS), 100 U/ml
penicillin, and 100µg/ml streptomycin sulfate (all from Gibco).
PDX-derived cell lines were cultured in Advanced DMEM/F12
(Gibco) supplemented with 8 % FBS, 2mM glutaMAX, 100
U/ml penicillin, and 100µg/ml streptomycin sulfate, and 20µM
rock kinase inhibitor Y-27632 (S1049; SelleckChem, Houston,
TX, USA). All cell lines were regularly tested to confirm
absence of mycoplasma with PCR-based method (PromoCell,
Heidelberg, Germany).
RNA Sequencing Data Analysis
To evaluateNRP1 andNRP2mRNA expression, RNA sequencing
datasets from previously published studies were downloaded
from GEO database of National Center for Biotechnology
Information (https://www.ncbi.nlm.nih.gov/geo/) (31) or
EGA European Genome-phenome Archive (https://ega-
archive.org/). Accession numbers were as following: GSE83518
(HUH6), EGAS00001004827/EGAD00001006621 (HB-282,
HB-295, HB-279, HB-284, HB-243), and GSE140520 (adult
primary hepatocytes) (32–34). Data was processed utilizing
Chipster software (https://chipster.rahtiapp.fi/) (35). Reads
were preprocessed using Trimmomatic and then aligned to
human reference genome Homo_sapiens.GRCh38.95 using
HISAT2 tool. Reads per genes were counted employing HTSeq.
Differential expression analysis was conducted with the edgeR-
package. Differentially expressed genes were then filtered using
cut-off criteria adjusted p-value < 0.05 and |logFC|≥1.0.
NRP2 Silencing
NRP2 expression was inhibited in HUH6 and HB-282 cells via
small interfering RNA (siRNA) transfection. Briefly, adherent
HUH6 cells were exposed to 100 nM and HB-282 cells to
25 nM of NRP2 ON-TARGETplus SMARTpool siRNA or ON-
TARGETplus non-targeting (NT) control siRNA (both from
Horizon Discovery, Cambridge, UK). Lipofectamine RNAiMAX
reagent (Invitrogen, Carlsbad, CA, USA) was used to deliver
siRNAs into the HUH6 cells and Dharmafect 4 (Horizon
Discovery) was utilized for HB-282 cells. Knockdown efficacy
was evaluated at mRNA and protein level 72 h after initiation
of transfection. Transfection efficacy was assessed with siGLO
Green transfection indicator (Horizon Discovery). A detailed
transfection protocol for HUH6 cells is described elsewhere
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(36), and HB-282 cells were transfected following manufacturer’s
instructions for Dharmafect.
RNA and Protein Extraction
A NucleoSpin RNA/Protein extraction kit was utilized for
total RNA and protein extractions (Macherey-Nagel, Düren,
Germany) following the manufacturer’s instructions.
TABLE 1 | Demographic variables and NRP expression in HBs.

















Quantitative Real-Time Polymerase Chain
Reaction
Reverse transcription was carried out using the Reverse
Transcriptase Core Kit (Eurogentec, Seraing, Belgium).
Quantitative polymerase chain reaction (qPCR) was performed
using MESA GREEN qPCR MasterMix Plus SYBR assay
(Eurogentec). The geometric mean of GAPDH and PPIG
expression served as a reference. Primer sequences were
designed as follows: GAPDH GGTCATCCATGACAAC
TTTGG (forward), CCATCCACAGTCTTCTGGGT (reverse);
NRP2 CTGTGGGTCATCCGTGAGGAC (forward), ATG




Equal amounts of protein were subjected to electrophoresis
using Mini-Protean TGX Stain-Free Gels (Bio-Rad, Hercules,
CA, USA) and then transferred onto polyvinyl fluoride
membrane. Blocking was performed with 5% non-fat milk
in Tris-Buffered Saline. Primary antibody incubations were
carried out at +4◦C for overnight (NRP1 at dilution 1:1,500,
ab81321, Abcam; NRP2 at dilution 1:800, sc-13117, Santa
Cruz). Secondary antibody incubation was performed at room
temperature for 1 h (1:10,000; #115-005-062 or #111-035-
144, Jackson ImmunoResearch, West Grove, PA, USA).
Protein bands were illuminated utilizing the Enhanced
FIGURE 1 | NRP1 and NRP2 expression in HB patient samples and normal liver. NRP1 and NRP2 expression was limited to LSCEs (arrowhead) in normal liver (n = 4)
(A–D). HB tumor cells demonstrated low/intermediate (10/20) (E,F) or high (10/20) (I,J) NRP1 immunoreactivity localized to the cell membrane and cytoplasm. NRP2
expression (G,H) was low/intermediate in 11/20 HBs. High NRP2 (K,L) immunoreactivity was observed in 9/20 of HBs. NRP2 was mainly detected in the cytoplasm
with lesser amounts in membranes (G,H,K,L). Scale bars: 50µm (A,C), 20µm (B,D).
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Chemiluminescence detection kit (Amersham ECL reagent;
GE Healthcare, Barrington, IL). Quantification was performed
with Image Lab Software 6.0 (Bio-Rad). NRP1 and NRP2
band intensities were normalized to amount of total protein
in corresponding lane (Supplementary Figure 1) utilizing
stain-free technology (37).
Viability Measurements
Cells were seeded into 96-well plates and transfected with
NRP2 or NT siRNA. Cell viability was measured utilizing
clonogenic assay and ATPlite assay (PerkinElmer, Waltham,
MA, USA) at 72 h post-transfection. For clonogenic assay,
transfected cells were seeded at low densities into 6-well
plates. After 72 h, cells were fixed with 4% paraformaldehyde,
permeabilized with 100% methanol, and consequently stained
with crystal violet solution. Images were collected with Bio-
Rad ChemiDoc XRS+ Imaging System. The number of
colonies were quantified with ImageJ software. ATPlite assay
was performed following the manufacturer’s instructions, and
luminescence was measured with an Enspire Multimode Plate
Reader (PerkinElmer).
Migration Assay
Cell migration was evaluated utilizing transwell migration inserts
(8µm pore size; Merck Millipore, Darmstadt, Germany). The
bottom of each insert was pre-coated with collagen I (0.1 mg/ml;
Sigma Aldrich, St. Louis, MO, USA), and the inserts were placed
into the 24-well plates containing normal cell culture medium.
NRP2 or NT siRNA transfected cells (at density of 50× 103/insert
for HUH6 cells and 20 × 103/insert for HB-282 cells) were
seeded to upper side of membrane in serum-free medium. After
40 h, cells were fixed with 4% paraformaldehyde, permeabilized
with 100% methanol and stained with crystal violet solution.
Non-migrated cells were removed from upper side of membrane
with cotton swab. In each insert, images were captured from
five randomly chosen fields with Eclipse TS100 microscope
supplemented with DS-Fi1 digital imaging system (magnification
10x; Nikon, Tokyo, Japan). The number of migrated cells was
assessed with ImageJ software.
Immunofluorescence Staining
NRP2 or NT siRNA transfected HUH6 cells were grown in
2-well chamber slides coated with collagen I for 72 h. Fixation
FIGURE 2 | NRP1 and NRP2 RNA and protein expression in HB cell lines. NRP1 mRNA expression was significantly higher in 4/6 HB cell lines investigated compared
to adult primary hepatocyte control (A). Similarly, NRP1 protein expression was elevated in same four cell lines (B) compared to pediatric primary hepatocytes.
Upregulated NRP2 expression was observed in 5/6 HB cell lines both at mRNA (C) and protein level (D). §Adjusted p-value < 0.05. aPH, adult primary hepatocytes;
pPH, pediatric primary hepatocytes. Band intensity is normalized to total protein expression of each lane. Normalization factor (NF) describing the amount of total
protein in lane in relation to other lanes is given beneath the bands (B,D).
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was performed with 4% paraformaldehyde. Following, 0.1%
Triton-X was used for permeabilization. Non-specific binding
was blocked with UltraVision Protein Block solution (Thermo
Scientific, Fremont, CA, USA). F-actin staining was carried out
with phalloidin-FITC (at dilution 1:500; P5282, Sigma Aldrich) at
room temperature for 1 h. Images were captured with Zeiss Axio
Imager M2 (objective: EC Plan Neofluar 40 × /0.75 Ph 2 M27)
(Carl-Zeiss, Oberkochen, Germany).
Statistical Analysis
For qPCR, protein analysis, viability assays, and migration
studies, three independent experiments were conducted.
Statistical significance was assessed with Student’s t-test utilizing
JMP Software (JMP Pro; version 15.1.0, SAS Institute Inc.).
A p-value < 0.05 was considered as statistically significant.
RNA-sequencing data was analyzed with edgeR-package and
significance level was set at adjusted p-value < 0.05.
RESULTS
NRPs Are Highly Expressed in HB Tissue
and Cell Lines
We assessed NRP1 and NRP2 expression in FFPE samples
collected from 20 HB patients treated at Helsinki University
Hospital between January 1, 1990 and December 31, 2016.
Demographic information of the patients is shown in Table 1.
Healthy liver samples from organ donors were used as controls.
Consistent with prior reports (28, 38), NRP1 and NRP2
expression was limited to LSECs in healthy liver; hepatocytes did
not display specific immunoreactivity (Figures 1A–D). All HBs
exhibited NRP1 expression; in 10/20 staining intensity was low
or intermediate, and 10/20 samples had high NRP1 expression
(Figures 1E,F,I,J, Table 1). NRP2 expression was observed in
19/20 HBs; it was low or intermediate in 11/20 and high in
8/20 samples (Figures 1G,H,K,L, Table 1). HB cells exhibited
both cytoplasmic andmembranous staining for NRP1 andNRP2.
Additionally, LSCEs and hepatic stellate cells showed high NRP1
and NRP2 immunoreactivity in HB tissue (Figures 1G–L).
Next, we evaluated NRP1 and NRP2 expression in six human
HB cell lines and primary hepatocyte cultures. NRP1 mRNA
was upregulated in four HB cell lines (HB-282, HB-295, HB-
279, HB-243) compared to primary hepatocytes (Figure 2A).
Similarly, these four cell lines demonstrated a 70- to 700-fold
increase in NRP1 protein levels compared to primary hepatocytes
(Figure 2B). Upregulation of NRP2 mRNA was noted in all
HB cell lines while expression in primary hepatocytes was
barely detectable (Figure 2C). At the protein level, HUH6,
HB-282, HB-295, HB-284, and HB-243 demonstrated striking
amounts of NRP2 (1,400- to 4,300-fold increase compared
to primary hepatocytes; Figure 2D). NRP2 protein expression
was undetectable in primary hepatocytes and HB-279 cells
(Figure 2D).
NRP2 Silencing in HUH6 and HB-282 Cell
Lines
Since NRP2 expression was prominent in five out of six
HB cell models, it was selected as the target for functional
studies. We performed NRP2 knockdown in HUH6 and HB-282
A B
C D
FIGURE 3 | NRP2 silencing in HB cells. In HUH6 cells, NRP2 mRNA
expression was reduced 75% after 72 h of NRP2 siRNA transfection
compared to NT control (A). Protein band intensity of NRP2 was 70% lower in
NRP2 siRNA treated cells in contrast to NT control cells (B). In HB-282 cells,
NRP2 expression was reduced 60% at mRNA and 70% at protein level in
NRP2 siRNA transfected cells compared to control cells (C,D). Bar plots are
presented as relative values of mean of three independent experiments ±
RSD. Band intensity is normalized to total protein expression of each lane.
Normalization factor (NF) describing the amount of total protein in lane in
relation to other lanes is given beneath the bands (B). **p-value < 0.01. NT,
non-targeting.
cells, which displayed the highest NRP2 mRNA expression. To
confirm the performance of the chosen transfection methods,
HUH6 and HB-282 cells were transfected with a transfection
indicator. Majority of the cells demonstrated sufficient intake
of siGLO Green (Supplementary Figures 2A–F). Following
transient siRNA transfections, NRP2 expression was reduced
70–75% at the mRNA and protein level in HUH6 cells
(Figures 3A,B) and 60–70% at mRNA and protein level in HB-
282 cells (Figures 3C,D).
Knockdown of NRP2 Attenuates HB Cell
Viability
To evaluate the impact of NRP2 silencing on cell growth
and survival, we performed a clonogenic assay. A statistically
significant reduction in the number of colonies was observed
in both HUH6 (Figures 4A–C) and HB-282 (Figures 4E–G)
cell lines, the decrease in colony numbers being 40 and
60%, respectively. The effect of NRP2 knockdown on ATP
availability was assessed as a secondary measure for cell viability.
Approximately a 30% decrease in ATP concentration was noted
in HUH6 (Figure 4D) and HB-282 (Figure 4H) cells.
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FIGURE 4 | Viability in HB cells transfected with NT or NRP2 siRNA. The number of colonies was decreased ∼40% after NRP2 knockdown in HUH6 cells (A–C) and
60% in HB-282 cells at 72 h post-transfection (E–G). ATP concentration decreased 30% after NRP2 silencing both in HUH6 (D) and HB-282 cells (H). Bar plots are
presented as relative values of mean of three independent experiments ± RSD. **p-value < 0.01, *p-value < 0.05. NT, non-targeting.
NRP2 Silencing Decreases Stress Fiber
Formation and Attenuates HB Cell Motility
A previous study byWittmann and colleagues demonstrated that
NRP2 expression is associated with increased motility of liver
carcinoma cells (28). We observed a reduced amount of actin
protrusions and depolymerization of stress fibers inNRP2 siRNA
treatedHUH6 (Figures 5E–H) andHB-282 (Figures 5M–P) cells
compared to NT siRNA treated control cells (Figures 5A–D,I–L).
Next, we investigated the motility of HUH6 and HB-282 cells
exploiting the transwell migration assay. A statistically significant
55% (HUH6) and 85% (HB-282) decrease in the number of
migrated cells was noted in HB cells with downregulated NRP2
expression cells (Figures 6B,C,E,F) compared to control cells
(Figures 6A,C,D,F).
DISCUSSION
NRPs have been associated with increased malignant potential
and poor prognosis in various human cancers (19, 22, 39–
41). In addition to their potential as biomarkers, efforts are
underway to develop NRP1 or NRP2 as therapeutic targets (42–
45). To the best of our knowledge, the present study is the first
to demonstrate that NRP1 and NRP2 are highly expressed in
HB. Furthermore, our observations link NRP2 expression with
increased cell survival, actin stress fiber polymerization, and
migration of HB cells (Figure 7). Currently, chemotherapy with
cisplatin and doxorubicin is one of the mainstays of HB therapy,
but multiorgan toxicity and chemoresistance limit the usability
of these agents (46–49). Therefore, there is a need to identify
tumor specific proteins to enable the development of targeted
treatments for HB.
In adults with hepatocellular carcinoma, NRP2 expression
correlates with shorter disease-free survival and overall
survival (19). Moreover, high NRP2 expression was noted
in de-differentiated tumors and mesenchymal hepatocellular
carcinoma cell lines (19, 28). We observed high NRP2 expression
in majority of HB tumors and in vitro models. Taken together,
it appears that NRP2 expression is a common feature in poorly
differentiated hepatic malignancies. Due to the limited number
of patient samples, NRP2 expression was not correlated with
clinical variables in this study. Therefore, in future investigations
with larger sample sets, the association of NRP2 with HB patient
survival should be explored.
NRP2 expression has been associated both with increased
proliferation rate as well as with the capability of tumor cells
to escape from programmed cell death in cancer cells (13, 50,
51). We observed decreased cell viability in NRP2 knockdown
cells, but further studies are needed to clarify whether this is a
consequence of lower proliferation rate or increased cell death.
Interestingly, a recent study linked upregulation of NRP2 with
cisplatin-resistance in neuroblastoma cells (52). Poor response to
current chemotherapeutical treatments, including cisplatin, have
been observed in 20–25% of HB tumors pointing out the need to
find approaches to overcome the chemoresistance (49). It would
be of interest to study whether cisplatin treatment combined with
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FIGURE 5 | NRP2 silencing reduces stress fiber formation and actin protrusions in HB cells. Nuclear staining with DAPI in NT (A,I) or NRP2 siRNA (E,M) treated cells.
Cells having undisturbed NRP2 expression (B,J) stained with F-actin demonstrated more prominent cellular protrusions (arrow) and cytoplasmic accumulation of
stress fibers compared to NRP2 knockdown cells (F,N). Close-up images (C,G,K,O) of (B,J) and (F,N) showing localization of stress fibers (arrowhead). Merged
images of DAPI and F-actin staining in NT control cells (D,L) and NRP2 knockdown cells (H,P). Scale bar: 20µm (A,B,D–F,H–J,L–N,P). NT, non-targeting.
NRP2 targeting could cause an even more drastic decrease in
cell viability in HB cells than cisplatin administration or NRP2
knockdown alone.
Actin stress fibers are a hallmark of mesenchymal phenotype,
and remodeling of actin cytoskeleton is a prerequisite for cancer
cell motility (53). Polymerized stress fibers form protrusive
structures named filipodia, lamellipodia, and invadopodia
directing the migration and invasion of cancer cells to new
locations (54). This process is a preliminary step in metastasis
formation (55). High NRP2 expression has been associated
with increased motility and invasiveness in cancer cell models
(28, 56, 57). In line with these findings, NRP2 silencing led
to depolymerization of actin stress fibers, and consequently
decreased the migration of HB cells. The importance of
NRP2 in pre-metastatic processes suggests that NRP2 targeted
interventions hold potential in themanagement of aggressiveHB.
A multitude of signaling mediators are known to interact
with NRPs. In breast cancer cells, neutralizing NRP2 antibody
blocked cytoplasmic C-X-C Motif Chemokine Receptor
4 (CXCR4) expression which was followed by decreased
tumor cell migration (22). Interestingly, upregulation of
CXCR4 was recently associated with the infiltration of pro-
tumorigenic macrophages, neutrophils, and dendritic cells
in HB tissue samples (58). Considering the NRP2-CXCR4
axis, NRP2 targeting might attenuate the growth of HB at
multiple levels. In addition to the direct effect on HB cells
observed in our study, anti-NRP2 approaches might disrupt the
tumor microenvironment.
Abnormal WNT/β-catenin signaling is observed in the
majority of HBs, and several studies have shown that inhibition
of WNT/β-catenin suppresses HB cell growth in vitro (7, 59–
61). Captivatingly, upregulation of secreted WNT antagonists
decreased NRP2 expression in osteosarcoma cell models
suggesting that NRP2 transcription is regulated by WNT
pathway (44). NRP2 expression has also been directly connected
to improved β-catenin stability with consequently increased
motility and invasiveness of gastrointestinal cancer cells (57).
Future investigations should explore whether upregulation
of NRP2 in HBs is linked to aberrant WNT/β-catenin
signaling activity.
Major limitations of this study were the rather low number
of patient samples and challenges linked to the siRNA mediated
silencing method. It is known that siRNAs may have off-target
effects (62). Therefore, it should be noted that the in vitro results
presented in this study may not be explicitly due to the NRP2
silencing. In the future studies, another silencing methods, such
as CRISPR-Cas9 mediated gene editing, should be considered to
overcome this issue.
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FIGURE 6 | NRP2 silencing decreases HB cell migration. After 40 h, decreased numbers of NRP2 siRNA treated HUH6 and HB-282 cells migrated through the
transwell membrane when compared to cells with an intact NRP2 expression (A,B,D,E); the relative cell migration was 2.2-fold higher in HUH6 and 6.2-fold higher in
HB-282 NT control cells compared to NRP2 silenced cells (C,F). Bar plots are presented as relative values of mean of three independent experiments ± RSD.
**p-value < 0.01. NT, non-targeting.
FIGURE 7 | Schematic illustration of the findings. Majority of HB patient samples demonstrated high NRP1 and/or NRP2 expression. Furthermore, NRP2 silencing led
to decreased cell viability and motility in HUH6 HB cell line.
In conclusion, NRPs are expressed in the majority of HBs
and further studies are warranted to evaluate their potential as
prognostic biomarkers. Moreover, RNA interference mediated
inhibition of NRP2 suppresses HB cell viability and motility
suggesting that NRP2 targeted interventions have potential in the
management of aggressive HB.
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